CancerDrs Find care

Lymphoma clinical trials in Florida

71 actively recruiting lymphoma trials at 50 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Florida:
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 3 Recruiting Network

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …

Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Florida:
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • Nicklaus Children's Hospital — Miami, Florida
Phase 3 Recruiting Industry

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…

Sponsor: Genmab
NCT ID: NCT06191744
Sites in Florida:
  • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 — Jacksonville, Florida
  • Advent Health /ID# 261578 — Orlando, Florida
  • Orlando Health Cancer Institute /ID# 260983 — Orlando, Florida
  • Moffitt Cancer Center /ID# 259487 — Tampa, Florida
Phase 3 Recruiting Industry

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…

Sponsor: BeiGene
NCT ID: NCT05100862
Sites in Florida:
  • Baptist Md Anderson Cancer Center — Jacksonville, Florida
  • Ascension Sacred Heart — Pensacola, Florida
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Florida:
  • Clermont Oncology Center ( Site 0046) — Clermont, Florida
  • Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
  • Florida Cancer Specialists - East ( Site 7002) — West Palm Beach, Florida
Phase 3 Recruiting Industry

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Florida:
  • Clermont Oncology Center ( Site 0182) — Clermont, Florida
  • Bioresearch Partner ( Site 0157) — Hialeah, Florida
  • Orlando Health Cancer Institute ( Site 0169) — Ocoee, Florida
  • Mid Florida Hematology and Oncology Center ( Site 0172) — Orange City, Florida
Phase 3 Recruiting Industry

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…

Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Florida:
  • Florida Oncology and Hematology — Fort Myers, Florida
  • Baptist Md Anderson Cancer Center — Jacksonville, Florida
  • Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • Cancer Specialists of North Florida -St Augustine — Saint Augustine, Florida
  • Florida Cancer Specialists East — West Palm Beach, Florida
Phase 3 Recruiting Industry

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Florida:
  • University of Miami — Coral Gables, Florida
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (here…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06074588
Sites in Florida:
  • Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001) — Jacksonville, Florida
  • Mid Florida Hematology and Oncology Center ( Site 0005) — Orange City, Florida
Phase 3 Recruiting Industry

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or margina…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Sites in Florida:
  • Boca Raton Clinical Research (BRCR) Global — Plantation, Florida
Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Florida:
  • Memorial Hospital West ( Site 5410) — Pembroke Pines, Florida
Phase 3 Recruiting Academic/Other

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New…

Sponsor: University College, London
NCT ID: NCT04685616
Sites in Florida:
  • University of Miami School of Medicine — Miami, Florida
Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Florida:
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Jupiter Medical Center — Jupiter, Florida
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Florida:
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • University of Florida Health Science Center - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • AdventHealth Orlando — Orlando, Florida
Phase 2 Recruiting Academic/Other

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Florida:
  • Florida Cancer Specialists North / Sarah Cannon Research Institute — Altamonte Springs, Florida
  • University of Miami/Sylvester Cancer Institute - Aventura — Aventura, Florida
  • Florida Cancer Specialists South / Sarah Cannon Research Institute — Bonita Springs, Florida
  • Florida Cancer Specialists South / Sarah Cannon Research Institute — Bradenton, Florida
  • Florida Cancer Specialists North / Sarah Cannon Research Institute — Brandon, Florida
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Florida:
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 2 Recruiting NIH

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Florida:
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • AdventHealth Orlando — Orlando, Florida
Phase 2 Recruiting Network

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Florida:
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 1, Phase 2 Recruiting Industry

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…

Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Florida:
  • Mayo Clinic - Jacksonville — Jacksonville, Florida
  • Mayo Clinic — Jacksonville, Florida
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Florida:
  • Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130) — Boca Raton, Florida
  • Baptist MD Anderson Cancer Center ( Site 0176) — Jacksonville, Florida
  • Mount Sinai Cancer Center ( Site 0140) — Miami Beach, Florida
  • Mid Florida Hematology and Oncology Center ( Site 0152) — Orange City, Florida
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Florida:
  • Johns Hopkins All Children's Hospital — St. Petersburg, Florida

Showing 25 of 71 trials with sites in Florida. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20